Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Faron Secures U.S. Rights to Patent Related to Traumakine
Details : The agreement clarifies Faron's intellectual property position in the U.S. ahead of any launch of Traumakine for the treatment of capillary leak and systemic inflammatory response syndromes including acute respiratory distress syndrome (ARDS) in the U.S.
Product Name : Traumakine
Product Type : Protein
Upfront Cash : Undisclosed
May 14, 2021
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Detailed analyses following INTEREST trial conclude glucocorticoids block the upregulation of CD73 in the lung capillaries and inhibit interferon signalling.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable